From: Antifungal prophylaxis in chemotherapy-associated neutropenia: a retrospective, observational study
 | AMB Period vs. AZ Period | |||
---|---|---|---|---|
 | AMB | AZ | Odds Ratio1 | p-value |
No. of Hospitalizations | 259 | 321 | Â | Â |
No. of Patients | 181 | 216 | Â | Â |
Mean Age2 | 49.6 yrs (19 – 86 yrs)3 | 50.3 yrs (18 – 83 yrs) |  | <0.0014 |
Gender | 65% male | 55% male | OR = 0.00 | 0.00095 |
Diagnoses | Â | Â | Â | Â |
NHL | 74 (29%) | 102 (32%) | OR = 0.96 | 0.97 |
Hodgkin's Disease | 11 (4%) | 19 (6%) | OR = 1.38 | 0.85 |
Myeloid Neoplasms | 96 (37%) | 111 (35%) | OR = 0.56 | 0.6 |
Lymphocytic Leukemia | 46 (18%) | 40 (12%) | OR = 0.58 | 0.66 |
Multiple Myeloma | 25 (10%) | 39 (12%) | OR = 1.16 | 0.9 |
Other | 7 (3%) | 10 (3%) | OR = 6.45 | 0.25 |
Therapy | Â | Â | Â | Â |
Mini-transplant | 14 (8%) | 15 (5%) | OR = 0.98 | 0.965 |
Allo-transplant | 3 (2%) | 23 (7%) | OR = 2.62 | 0.225 |
Auto-transplant | 39 (22%) | 42 (13%) | OR = 0.63 | 0.035 |
Chemotherapy | 113 (62%) | 136 (42%) | OR = 1.16 | 0.555 |
Other | 11(6%) | 19 (6%) | OR = 1.24 | 0.595 |
Twin-transplant | 1 (0.6%) | 0 | Â | Â |
Mean Length of Stay2 | 20.9 days (19–23 days) | 19.2 days (17.5–21.1 days) |  | 0.214 |
Mean Duration of therapy2 | 19.8 days (17.9–21.8 days) | 16.5 days (15–18.1 days) |  | 0.0094 |